Long-term effectiveness of a primary care practice facilitation program for chronic kidney disease management: an extended follow-up of a cluster-randomized FROM-J study

• Published in: Nephrology, dialysis, transplantation dialysis, transplantation, 2023-01, Vol.38 (1), p.158-166
• Main Authors: Imasawa, Toshiyuki, Saito, Chie, Kai, Hirayasu, Iseki, Kunitoshi, Kazama, Junichiro James, Shibagaki, Yugo, Sugiyama, Hitoshi, Nagata, Daisuke, Narita, Ichiei, Nishino, Tomoya, Hasegawa, Hajime, Honda, Hirokazu, Maruyama, Shoichi, Miyazaki, Mariko, Mukoyama, Masashi, Yasuda, Hideo, Wada, Takashi, Ishikawa, Yuichi, Tsunoda, Ryoya, Nagai, Kei, Okubo, Reiko, Kondo, Masahide, Hoshino, Junichi, Yamagata, Kunihiro
• Format: Article
• Language: English
• Subjects: Cardiovascular Diseases; Disease Progression; Follow-Up Studies; Glomerular Filtration Rate; Humans; Japan; Kidney; Primary Health Care; Renal Insufficiency, Chronic - complications
• ISSN: 0931-0509; 1460-2385
• DOI: 10.1093/ndt/gfac041

ABSTRACT Background Practice facilitation program by multidisciplinary care for primary care physicians (PCPs) is expected to improve chronic kidney disease (CKD) outcomes, but there is no clear evidence of its long-term effectiveness. We have previously performed a cluster-randomized controlled trial for 3.5 years (the Frontier of Renal Outcome Modifications in Japan (FROM-J) study) with two arms—group A without the program and group B with the program. We aimed to assess the long-term effectiveness of the practice facilitation program on CKD outcomes via an extended 10-year follow-up of the FROM-J study. Methods We enrolled patients who were in the FROM-J study. The primary composite endpoint comprised cardiovascular disease (CVD), renal replacement therapy initiation and a 50% decrease in the estimated glomerular filtration rate (eGFR). The secondary endpoints were survival rate, eGFR decline rate and collaboration rate between PCPs and nephrologists. Results The occurrence of the primary composite endpoint tended to be lower in group B (group A: 27.1% versus group B: 22.1%, P = 0.051). Furthermore, CVD incidence was remarkably lower in group B (group A: 10.5% versus group B: 6.4%, P = 0.001). Although both mortality and the rate of eGFR decline were identical between both groups, the eGFR decline rate was significantly better in group B than in group A only in patients with stage G3a at enrollment (group A: 2.35 ± 3.87 mL/min/1.73 m2/year versus group B: 1.68 ± 2.98 mL/min/1.73 m2/year, P = 0.02). The collaboration rate was higher in group B. Conclusions The CKD practice facilitation program for PCPs reliably decreases CVD events and may reduce the progression of cases to end-stage kidney disease. Graphical Abstract Graphical Abstract